40 related articles for article (PubMed ID: 19398326)
1. Surgeon and breast unit volume-outcome relationships in breast cancer surgery and treatment.
McDermott AM; Wall DM; Waters PS; Cheung S; Sibbering M; Horgan K; Kearins O; Lawrence G; Patnick J; Kerin MJ;
Ann Surg; 2013 Nov; 258(5):808-13; discussion 813-4. PubMed ID: 23989053
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer surgery and diagnosis-related groups (DRGs): patient classification and hospital reimbursement in 11 European countries.
Scheller-Kreinsen D; Quentin W; Geissler A; Busse R;
Breast; 2013 Oct; 22(5):723-32. PubMed ID: 23218742
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of 2-[
Naghavi-Behzad M; Gerke O; Kodahl AR; Vogsen M; Asmussen JT; Weber W; Hildebrandt MG; Kidholm K
Sci Rep; 2023 Sep; 13(1):16315. PubMed ID: 37770525
[TBL] [Abstract][Full Text] [Related]
4. Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands.
Schneider PP; Ramaekers BL; Pouwels X; Geurts S; Ibragimova K; de Boer M; Vriens B; van de Wouw Y; den Boer M; Pepels M; Tjan-Heijnen V; Joore M
Value Health; 2021 May; 24(5):668-675. PubMed ID: 33933235
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of prostate cancer - a Swedish prevalence-based register study.
Hao S; Östensson E; Eklund M; Grönberg H; Nordström T; Heintz E; Clements M
BMC Health Serv Res; 2020 May; 20(1):448. PubMed ID: 32434566
[TBL] [Abstract][Full Text] [Related]
6. Global treatment costs of breast cancer by stage: A systematic review.
Sun L; Legood R; Dos-Santos-Silva I; Gaiha SM; Sadique Z
PLoS One; 2018; 13(11):e0207993. PubMed ID: 30475890
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine.
Javan-Noughabi J; Rezapour A; Kassani A; Hatam N; Ahmadloo N
J Res Med Sci; 2018; 23():57. PubMed ID: 30057641
[TBL] [Abstract][Full Text] [Related]
8. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.
Muka T; Imo D; Jaspers L; Colpani V; Chaker L; van der Lee SJ; Mendis S; Chowdhury R; Bramer WM; Falla A; Pazoki R; Franco OH
Eur J Epidemiol; 2015 Apr; 30(4):251-77. PubMed ID: 25595318
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.
Guest JF; Panca M; Sladkevicius E; Gough N; Linch M
Sarcoma; 2013; 2013():725305. PubMed ID: 24302852
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.
Baffert S; Cottu P; Kirova YM; Mercier F; Simondi C; Bachelot T; Le Rhun E; Levy C; Gutierrez M; Madranges N; Moldovan C; Coudert B; Spaëth D; Serin D; Cotté FE; Benjamin L; Maillard C; Laulhere-Vigneau S; Durand-Zaleski I
BMC Health Serv Res; 2013 Oct; 13():456. PubMed ID: 24176086
[TBL] [Abstract][Full Text] [Related]
11. The Direct Medical Costs of Breast Cancer in Iran: Analyzing the Patient's Level Data from a Cancer Specific Hospital in Isfahan.
Davari M; Yazdanpanah F; Aslani A; Hosseini M; Nazari AR; Mokarian F
Int J Prev Med; 2013 Jul; 4(7):748-54. PubMed ID: 24049592
[TBL] [Abstract][Full Text] [Related]
12. The costs of breast cancer prior to and following diagnosis.
Broekx S; Den Hond E; Torfs R; Remacle A; Mertens R; D'Hooghe T; Neven P; Christiaens MR; Simoens S
Eur J Health Econ; 2011 Aug; 12(4):311-7. PubMed ID: 20306109
[TBL] [Abstract][Full Text] [Related]
13. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
[TBL] [Abstract][Full Text] [Related]
14. [Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France].
Perrier L; Sebban C; Philip I; Standaert B; Morelle M; Latour JF; Biron P; Philip T
Rev Epidemiol Sante Publique; 2002 Sep; 50(4):393-403. PubMed ID: 12442056
[TBL] [Abstract][Full Text] [Related]
15. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
16. [Acute leukemia].
Sánchez-Cortés E; González-Llaven J
Rev Invest Clin; 1997 May; 49 Suppl 1():103-7. PubMed ID: 9380982
[No Abstract] [Full Text] [Related]
17. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
18. Health care costs for treatment of disseminated breast cancer.
Dahlberg L; Lundkvist J; Lindman H
Eur J Cancer; 2009 Jul; 45(11):1987-91. PubMed ID: 19398326
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
